Khadijah M. Silver is a healthcare and life sciences journalist, attorney, and policy analyst with bylines at Law360, Institutional Investor, Popular Science and others. Silver holds a JD in health law from Boston University School of Law and is a member of the New York State Bar.
Boehringer Ingelheim has shown biosimilar manufacturers the way to win interchangeability with the world’s highest-grossing drug — but the company’s Cyltezo won't come out until July 2023. Will future Humira competitors have better luck winning an earlier launch date?
Independent and community pharmacies seek to prevent UHG and Change merging into a "corporate monster" that will stifle competition.
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
New healthcare marketplace policies seek to make the ACA more equitable by investing in low-income and underinsured communities, changing the rules in ways that upset some insurers but delight many state and consumer health advocates.
Enforcement of the No Surprises Act is still a work in progress, but CMS is ready to give out As for effort. Whether patients will agree with that grade still remains to be seen.
One of science's great puzzles is being solved by artificial intelligence and the answers shared freely on the internet. How can life sciences companies make the most of DeepMind's discoveries while protecting their own?
The clock is ticking down for payers and providers to comply with the No Surprises Act, which protects patients from balance billing for the most common ancillary medical services. Here's how to get your ducks in a row.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
Overturning a district court's decision that had earlier vacated the Medicare Advantage Overpayment Rule, the DC Circuit opened a Pandora's Box of DOJ False Claims Act litigation last week.
When is a skinny label skinny enough to protect a generic drug from claims of patent infringement? The answer remains up to interpretation after an important, controversial decision from the Federal Circuit.
Legislators threaten to ban settlements where branded companies "pay" generics makers to "delay" market entry, while drugmakers say the current framework balances competition and innovation. Who will prevail?
Many believe that the biosimilar industry can address the issue of spiraling drug costs, but first it has to make it through a thicket of challenges.
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
Despite mounting court and legislative scrutiny of pharmacy and prescription benefit manager practices, Amazon has chosen to throw its hat into the discount pharmacy ring. Could Amazon "disrupt" prescription drug delivery?
The justices ruled that the authority of the judges of the Patent Trial and Appeal Board is unconstitutional, but by giving the USPTO director greater oversight, the highest court likely saved this favored tool of generic patent challengers.
Six years after initially filing suit against CVS, insured customers of the pharmacy giant who charge that it misrepresented the "usual and customary" prices of drugs are finally getting their day in court.
To know how Chiquita Brooks-LaSure will lead the Centers for Medicare and Medicaid Services, we sat down with Matthew Hittle, a former senior adviser to Seema Verma, who led the agency under the former president.
While physicians face incredible pressures to consolidate or receive investment to survive, there are ethical, legal and practical considerations doctors must seriously consider before deciding to take private equity.